wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Editorial staff
     Editorial board
     For authors
Allergology Review

 Search in articles:
  Authority of Polish Society of Allergology

vol 5. no 3. September 2000  

 Original articles
Effect of pirenzepine, a selective antagonist of M1 receptors, after ipratropium bromide inhalation on FEV1 parameter in patients with COPD
Anna Dor, Maryla Krasnowska

Changes in neural control of the airways play an important role in bronchial obstructive diseases. Cholinergic tone is the only reversible component in patients with chronic obstructive pulmonary disease (COPD) and therefore it constitutes background for using anticholinergic drugs. Ipratropium bromide - a nonspecific anticholinergic (anti M2, M3 receptors) has been used in COPD for years with good results.
The aim of this study was to evaluate the influence of pirenzepine-a selective M1 muscarinic antagonist on lung ventilation in patients with COPD. Previously we have stated that inhaled pirenzepine caused in significant improvement in FEV1 parameter in patients with asthma but we have not noticed any statistical difference between pirenzepine and placebo.
15 patients with COPD (2 women, mean age 63 years) entered the double blind placebo controlled study. During two days the patients inhaled 0.5mg pirenzepine or placebo (0.9% NaCl) after an inhalation of 0.250 mg ipratropium bromide. Spirometric measurement was performed before the test and after inhalation of ipratropium bromide and 20, 40, 60 min after inhalation of pirenzepine or placebo. We demonstrated that pirenzepine dose of 0.5 mg after inhalation of ipratropium bromide didn't cause any FEV1 improvement in patients with COPD.
Alergia Astma Immunologia, 2000, 5(3), 193-196

keywords: przewlekła obturacyjna choroba płuc (POChP), blokery receptorów muskarynowych, leki antycholinergiczne, FEV1, bromek ipratropium, pirenzepina, chronic obstructive pulmonary disease (COPD), muscarinic antagonist, anticholinergic drugs, FEV1, ipratropium br

pages: from 193 to 196

estimated time of download (76 kB)
broadband speed:561282565121024[kbps]

You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.

Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2021 Mediton Publishing House | All rights reserved.